P100 Efficacy of anifrolumab in multi-refractory skin manifestations of systemic lupus erythematosus: case series

Documenti analoghi

• Anifrolumab for the treatment of refractory chilblain lupus erythematosus
  di: Michael J. Woodbury, BS, et al.
  Pubblicazione: (2024-06-01)
• Comparative histopathologic analysis of COVID-19-associated pseudo-chilblains (“COVID-toes”), with idiopathic pernio, and chilblains lupus erythematosus
  di: Taylor Harp, DO, et al.
  Pubblicazione: (2025-08-01)
• Chilblain lupus erythematosus associated with erdafitinib therapy in a patient with metastatic bladder cancer
  di: Amanda Truong, MD, PhD, et al.
  Pubblicazione: (2024-12-01)
• Flare of bullous lupus erythematosus in patients treated with anifrolumab for discoid lupus erythematosus: 2 cases
  di: Cécile Lesort, MD, et al.
  Pubblicazione: (2025-04-01)
• Successful treatment of recalcitrant cutaneous lupus erythematosus with anifrolumab in patients without systemic lupus erythematosus
  di: Bishoy Abdelmalik, BS, et al.
  Pubblicazione: (2025-01-01)